Breaking news in heart failure: ESC Guidelines 2016, non-steroidal mineralocorticoid receptor antagonist, and alternate site CRT pacing

被引：0
|
作者：
Luescher, Thomas F. [1 ]
机构：
[1] Zurich Heart House,Careum Campus,Moussonstr 4, CH-8091 Zurich, Switzerland
来源：
EUROPEAN HEART JOURNAL | 2016年 / 37卷 / 27期
关键词：
CARDIOVASCULAR RISK; OUTCOMES; ASSOCIATION; EPLERENONE; FINERENONE;
D O I：
10.1093/eurheartj/ehw306
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：2085 / 2087
页数：3
相关论文
共 45 条
  • [41] Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction
    Lachaux, Marianne
    Barrera-Chimal, Jonatan
    Nicol, Lionel
    Remy-Jouet, Isabelle
    Renet, Sylvanie
    Dumesnil, Anais
    Wecker, Didier
    Richard, Vincent
    Kolkhof, Peter
    Jaisser, Frederic
    Ouvrard-Pascaud, Antoine
    Mulder, Paul
    DIABETES OBESITY & METABOLISM, 2018, 20 (10): : 2399 - 2407
  • [42] A non-steroidal antagonist of mineralocorticoid receptor (MR) protects from coronary reserve loss and diastolic dysfunction worsened by exercise in mice with cardiomyocyte-specific MR overexpression
    Ouvrard-Pascaud, A.
    Gueret, A.
    Thireau, J.
    Nicol, L.
    Fazal, L.
    Delcayre, C.
    Richard, S.
    Richard, V.
    Jaisser, F.
    Kolkhof, P.
    Mulder, P.
    EUROPEAN HEART JOURNAL, 2016, 37 : 111 - 111
  • [43] Pharmacokinetics of the Novel, Selective, Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in Healthy Volunteers: Results from an Absolute Bioavailability Study and Drug–Drug Interaction Studies In Vitro and In Vivo
    Roland Heinig
    Michael Gerisch
    Anna Engelen
    Johannes Nagelschmitz
    Stephanie Loewen
    European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43 : 715 - 727
  • [44] Pharmacokinetics of the Novel, Selective, Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in Healthy Volunteers: Results from an Absolute Bioavailability Study and Drug-Drug Interaction Studies In Vitro and In Vivo
    Heinig, Roland
    Gerisch, Michael
    Engelen, Anna
    Nagelschmitz, Johannes
    Loewen, Stephanie
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2018, 43 (06) : 715 - 727
  • [45] A four-in-one first-in-human study to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and concentration-QTc relationship of HRS-1780, a selective non-steroidal mineralocorticoid receptor antagonist, in healthy men
    Shen, Qi
    Li, Lingzhi
    Qian, Weilin
    Dong, Xue
    Bao, Manchen
    Huang, Rong
    Li, Na
    Ye, Zi
    Cheng, Gang
    Wang, Quanren
    Shen, Kai
    Luo, Zhu
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2024, 33 (10) : 1083 - 1093
12345